Bright Minds’ BMB-101 Hold Exposes a Recurring Failure in Preclinical-to-IND Translation
FDA's partial hold on Bright Minds' BMB-101 for pediatric epilepsy, citing mouse toxicity and inadequate data, reveals a preclinical...
FDA's partial hold on Bright Minds' BMB-101 for pediatric epilepsy, citing mouse toxicity and inadequate data, reveals a preclinical...
A Phase 1 multiple sclerosis patient died 44 days after a zola-cel infusion. BMS says confounding factors prevent it...
FDA granted four DMD antisense oligonucleotide accelerated approvals on ~1 percentage-point dystrophin increases. With $967M in annual revenue on...
Newron's investigators assessed three of four evenamide deaths as unrelated. The FDA, looking at the same events pooled across...
FDA extended its denecimig BLA review over unnamed facility remediation failures, exposing the manufacturing blind spot that nearly every...
AB Science buried a five-inspector "for cause" GCP inspection inside a financial calendar update. Masitinib's ALS trial and three...
FDA's August 2026 warning letter to Fresenius Kabi's Ogden, Utah plant exposes how sponsor oversight of CMOs fails long...
Orexo AB settled a 6-year DOJ opioid-marketing investigation for $4M, but the press release names no conduct, no victims,...
EMA revoked Tavneos (avacopan) in August 2026 over GCP breaches in the pivotal ADVOCATE trial. FDA approved the same...
Scholar Rock dropped Novo's Catalent plant from its SMA drug refiling after an OAI inspection. The compliance rot was...